Global and Chinese urokinase industry development status survey and
investment prospect analysis report
According to the region, the income in China is the highest, reaching 8257%
in 2019. In 2019, the global urokinase market size reached 2.4 billion yuan and
is expected to reach 3.6 billion yuan in 2026, with a compound annual growth
rate (CAGR) of 61%. In 2019, the global urokinase market reached 2.4 billion
yuan and is expected to reach 3.6 billion yuan in 2026, with a compound annual
growth rate (CAGR) of 61%
Qingdao Kangyuan Biopharmaceutical Group was established in 1991 and was
recognized as the "hidden champion" of the domestic manufacturing industry in
2018.
The group now covers an area of more than 1,000 mu. It has two raw
material pharmaceutical factories of Qingdao Kangyuan Pharmaceutical and Qingdao
Jiulong Biopharmaceuticals, two preparation factories of Qingdao Huamaishi
Pharmaceutical and Qingdao Guanlong Biopharmaceuticals, as well as 5 wholly
foreign-owned, A joint-venture pharmaceutical enterprise; owns 37 biological
APIs and 59 formulations, and has formed a complete industrial chain from basic
raw materials to APIs to formulations, from China to the world.